Why Dynavax's Stock Is Trading Higher Today

Loading...
Loading...

Dynavax DVAX shares are trading higher on Friday amid strength in vaccine stocks for the session. The company on Thursday announced a collaboration with Mount Sinai to develop a universal flu vaccine candidate with CpG 1018 adjuvant.

Dynavax Technologies Corp is a clinical-stage biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. It's current product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Dynavax operates in the business segment the discovery and development of biopharmaceutical products. Its Toll-like Receptor Immune Modulation Platform technology play a vital role in innate immunity and subsequent adaptive immunity. Signaling through these receptors is triggered by the binding of a variety of pathogen-associated molecules and is essential to the generation of innate immunity.

Dynavax shares were trading up 20.55% at $11.44 during the time of publication on Friday. The stock has a 52-week high of $11.81 and a 52-week low of $1.80.

Posted In: NewsHealth CareGeneralwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...